Complement evasion by Bordetella pertussis: implications for improving current vaccines

Journal of Molecular Medicine

Volumn 93, Issue 4, 2015, Pages 395-402

  Jongerius, Ilse ^a,b   Schuijt, Tim J ^a,c   Mooi, Frits R ^a   Pinelli, Elena ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c DEPARTMENT OF SURGERY   (Netherlands)

Author keywords

Bordetella pertussis; Complement; Evasion; Innate immunity; Vaccine

Indexed keywords

COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C2; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5B; COMPLEMENT MEMBRANE ATTACK COMPLEX; OUTER MEMBRANE PROTEIN A; PERTUSSIS VACCINE; PROTEIN; PROTEIN VAG8; UNCLASSIFIED DRUG; COMPLEMENT;

ADAPTIVE IMMUNITY; BACTERICIDAL ACTIVITY; BINDING SITE; BORDETELLA PERTUSSIS; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; COMPLEMENT SYSTEM; DOWN REGULATION; HOST RESISTANCE; HUMAN; HUMORAL IMMUNITY; IMMUNE EVASION; INNATE IMMUNITY; LYMPHOCYTE DIFFERENTIATION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PATHOGENESIS; PERTUSSIS; PHAGOCYTOSIS; REVIEW; TH17 CELL; ANIMAL; IMMUNOLOGY;

ANIMALS; BORDETELLA PERTUSSIS; COMPLEMENT SYSTEM PROTEINS; HUMANS; IMMUNITY, INNATE; PERTUSSIS VACCINE; WHOOPING COUGH;

EID: 84925516302     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-015-1259-1     Document Type: Review

References (61)

1. Warfel JM, Beren J, Merkel TJ (2012) Airborne transmission of Bordetella pertussis. J Infect Dis 206(6):902–906
2. Mattoo S, Cherry JD (2005) Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev 18(2):326–382
3. Weiss AA, Hewlett EL (1986) Virulence factors of Bordetella pertussis. Annu Rev Microbiol 40:661–686
4. Paddock CD, Sanden GN, Cherry JD, Gal AA, Langston C, Tatti KM, Wu KH, Goldsmith CS, Greer PW, Montague JL et al (2008) Pathology and pathogenesis of fatal Bordetella pertussis infection in infants. Clin Infect Dis Off Publ Infec Dis Soc Am 47(3):328–338
5. Cherry JD (2013) Pertussis: challenges today and for the future. PLoS Pathog 9(7):e1003418
6. Mooi FR, NA VDM, De Melker HE (2013) Pertussis resurgence: waning immunity and pathogen adaptation—two sides of the same coin. Epidemiol Infect 142(4):685–694
7. van der Ark AA, Hozbor DF, Boog CJ, Metz B, van den Dobbelsteen GP, van Els CA (2012) Resurgence of pertussis calls for re-evaluation of pertussis animal models. Expert Rev Vaccines 11(9):1121–1137
8. He Q, Mertsola J (2008) Factors contributing to pertussis resurgence. Future Microbiol 3(3):329–339
9. Cherry JD (2012) Epidemic pertussis in 2012—the resurgence of a vaccine-preventable disease. N Engl J Med 367(9):785–787
10. Zipfel PF, Hallstrom T, Riesbeck K (2013) Human complement control and complement evasion by pathogenic microbes—tipping the balance. Mol Immunol 56(3):152–160
11. Walport MJ (2001) Complement. Second of two parts. N Engl J Med 344(15):1140–1144
12. Walport MJ (2001) Complement. First of two parts. N Engl J Med 344(14):1058–1066
13. Muller-Eberhard HJ (1986) The membrane attack complex of complement. Annu Rev Immunol 4:503–528
14. Ricklin D, Hajishengallis G, Yang K, Lambris JD (2010) Complement: a key system for immune surveillance and homeostasis. Nat Immunol 11(9):785–797
15. Kolev M, Le Friec G, Kemper C (2014) Complement—tapping into new sites and effector systems. Nat Rev Immunol 14(12):811–820
16. Bjornson AB, Mellencamp MA, Schiff GM (1991) Complement is activated in the upper respiratory tract during influenza virus infection. Am Rev Respir Dis 143(5 Pt 1):1062–1066
17. Persson CG, Erjefalt I, Alkner U, Baumgarten C, Greiff L, Gustafsson B, Luts A, Pipkorn U, Sundler F, Svensson C et al (1991) Plasma exudation as a first line respiratory mucosal defence. Clin Exp Allergy J Br Soc Allergy Clin Immunol 21(1):17–24
18. Watford WT, Ghio AJ, Wright JR (2000) Complement-mediated host defense in the lung. Am J Physiol Lung Cell Mol Physiol 279(5):L790–L798
19. Carroll MC, Isenman DE (2012) Regulation of humoral immunity by complement. Immunity 37(2):199–207
20. Kemper C, Kohl J (2013) Novel roles for complement receptors in T cell regulation and beyond. Mol Immunol 56(3):181–190
21. Kemper C, Atkinson JP (2007) T-cell regulation: with complements from innate immunity. Nat Rev Immunol 7(1):9–18
22. Zhou W (2012) The new face of anaphylatoxins in immune regulation. Immunobiology 217(2):225–234
23. Kolev M, Le Friec G, Kemper C (2013) The role of complement in CD4(+) T cell homeostasis and effector functions. Semin Immunol 25(1):12–19
24. Fang C, Zhang X, Miwa T, Song WC (2009) Complement promotes the development of inflammatory T-helper 17 cells through synergistic interaction with Toll-like receptor signaling and interleukin-6 production. Blood 114(5):1005–1015
25. Higgs R, Higgins SC, Ross PJ, Mills KH (2012) Immunity to the respiratory pathogen Bordetella pertussis. Mucosal Immunol 5(5):485–500
26. Goebel EM, Wolfe DN, Elder K, Stibitz S, Harvill ET (2008) O antigen protects Bordetella parapertussis from complement. Infect Immun 76(4):1774–1780
27. Burns VC, Pishko EJ, Preston A, Maskell DJ, Harvill ET (2003) Role of Bordetella O antigen in respiratory tract infection. Infect Immun 71(1):86–94
28. Kugelberg E, Gollan B, Tang CM (2008) Mechanisms in Neisseria meningitidis for resistance against complement-mediated killing. Vaccine 26(Suppl 8):I34–I39
29. Loh E, Kugelberg E, Tracy A, Zhang Q, Gollan B, Ewles H, Chalmers R, Pelicic V, Tang CM (2013) Temperature triggers immune evasion by Neisseria meningitidis. Nature 502(7470):237–240
30. Conover MS, Sloan GP, Love CF, Sukumar N, Deora R (2010) The Bps polysaccharide of Bordetella pertussis promotes colonization and biofilm formation in the nose by functioning as an adhesin. Mol Microbiol 77(6):1439–1455
31. Geurtsen J, Fae KC, van den Dobbelsteen GP (2014) Importance of (antibody-dependent) complement-mediated serum killing in protection against Bordetella pertussis. Expert Rev Vaccines 13(10):1229–1240
32. Ganguly T, Johnson JB, Kock ND, Parks GD, Deora R (2014) The Bordetella pertussis Bps polysaccharide enhances lung colonization by conferring protection from complement-mediated killing. Cell Microbiol 16(7):1105–1118
33. Fernandez RC, Weiss AA (1994) Cloning and sequencing of a Bordetella pertussis serum resistance locus. Infect Immun 62(11):4727–4738
34. Barnes MG, Weiss AA (2001) BrkA protein of Bordetella pertussis inhibits the classical pathway of complement after C1 deposition. Infect Immun 69(5):3067–3072
35. Noofeli M, Bokhari H, Blackburn P, Roberts M, Coote JG, Parton R (2011) BapC autotransporter protein is a virulence determinant of Bordetella pertussis. Microb Pathog 51(3):169–177
36. Zeerleder S (2011) C1-inhibitor: more than a serine protease inhibitor. Semin Thromb Hemost 37(4):362–374
37. Marr N, Luu RA, Fernandez RC (2007) Bordetella pertussis binds human C1 esterase inhibitor during the virulent phase, to evade complement-mediated killing. J Infect Dis 195(4):585–588
38. Arico B, Miller JF, Roy C, Stibitz S, Monack D, Falkow S, Gross R, Rappuoli R (1989) Sequences required for expression of Bordetella pertussis virulence factors share homology with prokaryotic signal transduction proteins. Proc Natl Acad Sci U S A 86(17):6671–6675
39. Marr N, Shah NR, Lee R, Kim EJ, Fernandez RC (2011) Bordetella pertussis autotransporter Vag8 binds human C1 esterase inhibitor and confers serum resistance. PLoS One 6(6):e20585
40. Mooi FR, van Loo IH, van Gent M, He Q, Bart MJ, Heuvelman KJ, de Greeff SC, Diavatopoulos D, Teunis P, Nagelkerke N et al (2009) Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. Emerg Infect Dis 15(8):1206–1213
41. Lathem WW, Bergsbaken T, Welch RA (2004) Potentiation of C1 esterase inhibitor by StcE, a metalloprotease secreted by Escherichia coli O157:H7. J Exp Med 199(8):1077–1087
42. Lathem WW, Grys TE, Witowski SE, Torres AG, Kaper JB, Tarr PI, Welch RA (2002) StcE, a metalloprotease secreted by Escherichia coli O157:H7, specifically cleaves C1 esterase inhibitor. Mol Microbiol 45(2):277–288
43. Berggard K, Johnsson E, Mooi FR, Lindahl G (1997) Bordetella pertussis binds the human complement regulator C4BP: role of filamentous hemagglutinin. Infect Immun 65(9):3638–3643
44. Berggard K, Lindahl G, Dahlback B, Blom AM (2001) Bordetella pertussis binds to human C4b-binding protein (C4BP) at a site similar to that used by the natural ligand C4b. Eur J Immunol 31(9):2771–2780
45. Fernandez RC, Weiss AA (1998) Serum resistance in bvg-regulated mutants of Bordetella pertussis. FEMS Microbiol Lett 163(1):57–63
46. Schneider MC, Exley RM, Ram S, Sim RB, Tang CM (2007) Interactions between Neisseria meningitidis and the complement system. Trends Microbiol 15(5):233–240
47. Jarva H, Jokiranta TS, Wurzner R, Meri S (2003) Complement resistance mechanisms of streptococci. Mol Immunol 40(2–4):95–107
48. Thern A, Stenberg L, Dahlback B, Lindahl G (1995) Ig-binding surface proteins of Streptococcus pyogenes also bind human C4b-binding protein (C4BP), a regulatory component of the complement system. J Immunol 154(1):375–386
49. Wooster DG, Maruvada R, Blom AM, Prasadarao NV (2006) Logarithmic phase Escherichia coli K1 efficiently avoids serum killing by promoting C4bp-mediated C3b and C4b degradation. Immunology 117(4):482–493
50. Amdahl H, Jarva H, Haanpera M, Mertsola J, He Q, Jokiranta TS, Meri S (2011) Interactions between Bordetella pertussis and the complement inhibitor factor H. Mol Immunol 48(4):697–705
51. Meri T, Amdahl H, Lehtinen MJ, Hyvarinen S, McDowell JV, Bhattacharjee A, Meri S, Marconi R, Goldman A, Jokiranta TS (2013) Microbes bind complement inhibitor factor H via a common site. PLoS Pathog 9(4):e1003308
52. Gouw D, Jonge MI, Hermans PW, Wessels HJ, Zomer A, Berends A, Pratt C, Berbers GA, Mooi FR, Diavatopoulos DA (2014) Proteomics-identified Bvg-activated autotransporters protect against Bordetella pertussis in a mouse model. PLoS One 9(8):e105011
53. Santolaya ME, O’Ryan ML, Valenzuela MT, Prado V, Vergara R, Munoz A, Toneatto D, Grana G, Wang H, Clemens R et al (2012) Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 379(9816):617–624
54. Schneider MC, Exley RM, Chan H, Feavers I, Kang YH, Sim RB, Tang CM (2006) Functional significance of factor H binding to Neisseria meningitidis. J Immunol 176(12):7566–7575
55. Madico G, Welsch JA, Lewis LA, McNaughton A, Perlman DH, Costello CE, Ngampasutadol J, Vogel U, Granoff DM, Ram S (2006) The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol 177(1):501–510
56. Serruto D, Rappuoli R, Scarselli M, Gros P, van Strijp JA (2010) Molecular mechanisms of complement evasion: learning from staphylococci and meningococci. Nat Rev Microbiol 8(6):393–399
57. Meri S, Jordens M, Jarva H (2008) Microbial complement inhibitors as vaccines. Vaccine 26(Suppl 8):I113–I117
58. Santi I, Maione D, Galeotti CL, Grandi G, Telford JL, Soriani M (2009) BibA induces opsonizing antibodies conferring in vivo protection against group B Streptococcus. J Infect Dis 200(4):564–570
59. Schachern PA, Tsuprun V, Ferrieri P, Briles DE, Goetz S, Cureoglu S, Paparella MM, Juhn S (2014) Pneumococcal PspA and PspC proteins: potential vaccine candidates for experimental otitis media. Int J Pediatr Otorhinolaryngol 78(9):1517–1521
60. Katsura H, Piao Z, Iwatsuki-Horimoto K, Akeda Y, Watanabe S, Horimoto T, Oishi K, Kawaoka Y (2014) A bivalent vaccine based on a replication-incompetent influenza virus protects against Streptococcus pneumoniae and influenza virus infection. J Virol 88(22):13410–13417
61. Grondahl-Yli-Hannuksela K, Viander M, Mertsola J, He Q (2013) Increased risk of pertussis in adult patients with mannose-binding lectin deficiency. APMIS Acta Pathol Microbiol Immunol Scand 121(4):311–315